Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

[1]  E. Akporiaye,et al.  MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. , 2007, Vaccine.

[2]  L. Pease,et al.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. , 2007, Cancer research.

[3]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[4]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[5]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[6]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[7]  B. Longenecker,et al.  MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment , 2001, Glycoconjugate Journal.

[8]  A. Vlad,et al.  MUC1 immunobiology: from discovery to clinical applications. , 2004, Advances in immunology.

[9]  E. Celis,et al.  Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  D. Kufe,et al.  Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1‐positive carcinoma cells , 2003, Immunology.

[11]  G. Dranoff.  GM-CSF-secreting melanoma vaccines , 2003, Oncogene.

[12]  K. Washington,et al.  Pathology of mouse models of intestinal cancer: consensus report and recommendations. , 2003, Gastroenterology.

[13]  B. Longenecker,et al.  Mucin 1-Specific Immunotherapy in a Mouse Model of Spontaneous Breast Cancer , 2003, Journal of immunotherapy.

[14]  B. Longenecker,et al.  Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. , 2002, Biochemistry.

[15]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.

[16]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jonathan J. Lewis,et al.  T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Hölscher,et al.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.

[19]  D. Speiser,et al.  CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide , 2002, The Journal of Immunology.

[20]  S. Gendler,et al.  MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  T. Ratliff,et al.  APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells1 , 2000, The Journal of Immunology.

[22]  M. J. Tevethia,et al.  Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1 , 2000, The Journal of Immunology.

[23]  Jilly F. Evans,et al.  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000, American Journal of Gastroenterology.

[24]  E. Davila,et al.  Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor Activity1 , 2000, The Journal of Immunology.

[25]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[26]  E. Raz,et al.  Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism , 2000, Nature Biotechnology.

[27]  H. Grey,et al.  Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma , 2000, Journal of immunotherapy.

[28]  C. Bonifer,et al.  Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. , 2000, The American journal of pathology.

[29]  K. Sheahan,et al.  The relationship between cyclooxygenase-2 expression and colorectal cancer. , 1999, JAMA.

[30]  E. Celis,et al.  A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. , 1999, Journal of immunotherapy.

[31]  T. Ponchon,et al.  Management of Duodenal Adenomas in Familial Adenomatous Polyposis , 1999, Endoscopy.

[32]  Å. Andreassen,et al.  Neonatal exposure to the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. , 1999, Carcinogenesis.

[33]  H. Grey,et al.  Fine specificity and MHC restriction of trinitrophenyl-specific CTL. , 1999, Journal of immunology.

[34]  T. Jakob,et al.  Bacterial DNA and CpG–Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL–12 Production: Implications for the Augmentation of Th1 Responses , 1999, International Archives of Allergy and Immunology.

[35]  E. Jaffee,et al.  Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. , 1998, Human gene therapy.

[36]  M. Hollingsworth,et al.  Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. , 1998, Cancer research.

[37]  O. Nilsson,et al.  Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.

[38]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[39]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[40]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Poppema,et al.  Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy , 1996, Cancer Immunology, Immunotherapy.

[42]  Kim Ys,et al.  Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. , 1996 .

[43]  Y. Kim,et al.  Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. , 1996, Oncology research.

[44]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[45]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[46]  D. Ota,et al.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.

[47]  T. Irimura,et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.

[48]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[49]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[51]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.